Medicsight, Ziosoft ink U.S. partnership
Medicsight has entered into an agreement with Ziosoft that includes the integration of Medicsight’s ColonCAD software and Ziosoft’s Ziostation technology as well as distribution of both technologies by Ziosoft in the U.S.
London-based Medicsight received U.S. regulatory clearance for clinical use of its technology in May. Medicsight’s ColonCAD is designed to assist radiologists during their review of CT colonography images by automatically highlighting potential colorectal polyps on the CT image. The regulatory clearance was supported by a large clinical trial involving 15 radiologist readers who each reviewed 112 patient CT colonography cases. The clinical trial results demonstrated that, when assisted by ColonCAD, radiologists’ accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading.
Ziosoft, based in Redwood City, Calif., holds numerous clearances for a variety of applications for its supercomputing visualization and functional analytics technology. Medicsight and Ziosoft have been partnering in Europe prior to the U.S. clearance of ColonCAD software.
“Both of our companies provide highly accurate and reproducible image visualization and functional analytics software to aid clinicians in diagnoses and treatment planning,” said Rob Royea, president and COO for Ziosoft. “We look forward to bringing our collective technologies to radiologists and other healthcare providers in support of excellence in patient care.”
One of the first U.S. sites to use the combined Medicsight and Ziosoft technologies will be the University of Wisconsin School of Medicine and Public Health Madison (UWH).
“CTC will definitely benefit from the pairing of these companies which are two recognized leaders in the advanced visualization field,” said Perry J. Pickhardt, professor of radiology at UWH.
London-based Medicsight received U.S. regulatory clearance for clinical use of its technology in May. Medicsight’s ColonCAD is designed to assist radiologists during their review of CT colonography images by automatically highlighting potential colorectal polyps on the CT image. The regulatory clearance was supported by a large clinical trial involving 15 radiologist readers who each reviewed 112 patient CT colonography cases. The clinical trial results demonstrated that, when assisted by ColonCAD, radiologists’ accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading.
Ziosoft, based in Redwood City, Calif., holds numerous clearances for a variety of applications for its supercomputing visualization and functional analytics technology. Medicsight and Ziosoft have been partnering in Europe prior to the U.S. clearance of ColonCAD software.
“Both of our companies provide highly accurate and reproducible image visualization and functional analytics software to aid clinicians in diagnoses and treatment planning,” said Rob Royea, president and COO for Ziosoft. “We look forward to bringing our collective technologies to radiologists and other healthcare providers in support of excellence in patient care.”
One of the first U.S. sites to use the combined Medicsight and Ziosoft technologies will be the University of Wisconsin School of Medicine and Public Health Madison (UWH).
“CTC will definitely benefit from the pairing of these companies which are two recognized leaders in the advanced visualization field,” said Perry J. Pickhardt, professor of radiology at UWH.